Literature DB >> 12890612

Identifying and modulating disulfide formation in the biopharmaceutical production of a recombinant protein vaccine candidate.

Anne Bouvier1, Jaymi Chapline, Renee Boerner, Shanthini Jeyarajah, Susan Cook, Prathima S Acharya, Ian Henderson, Jeffrey L Schrimsher, Scot R Shepard.   

Abstract

Structural conversion of the serotype A recombinant botulinum neurotoxin heavy chain fragment (rBoNTA(Hc)) produced intracellularly in Pichia pastoris yeast was observed and characterized during purification development efforts. A pH screening study captured the transformation stages of the original recovered species into its derived counterpart and a number of analytical tools such as peptide mapping by LC/MS confirmed the formation of a disulfide bond, especially in samples of neutral to basic pH. A cation exchange chromatographic method proved useful in following the incidence of the reaction in various rBoNTA(Hc) samples. The disulfide formation kinetics were characterized using a one-quarter quadratic factorial design, following the investigation and development of controlled oxidation conditions using cysteine and cystamine as the redox pair. Temperature, pH and concentration of the redox pair had a significant effect on the yield and rate of the disulfide formation. This controlled reaction was eventually introduced as a functional unit operation in the purification process. The summation of preliminary scale-up and potency data showed scalability and robustness in the production of an active disulfide-bonded form of a recombinant botulism vaccine candidate. The presence of the disulfide bond did not effect the vaccine potency and it enhanced the molecule's thermal stability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890612     DOI: 10.1016/s0168-1656(03)00106-8

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  4 in total

1.  Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.

Authors:  Mengfei Ho; Li-Hsin Chang; Melissa Pires-Alves; Baskaran Thyagarajan; Jordan E Bloom; Zhengrong Gu; Karla K Aberle; Sasha A Teymorian; Yuka Bannai; Steven C Johnson; Joseph J McArdle; Brenda A Wilson
Journal:  Protein Eng Des Sel       Date:  2010-11-04       Impact factor: 1.650

2.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

3.  Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.

Authors:  Philip A Band; Steven Blais; Thomas A Neubert; Timothy J Cardozo; Konstantin Ichtchenko
Journal:  Protein Expr Purif       Date:  2010-01-04       Impact factor: 1.650

4.  Subtractive Proteomics and Immuno-informatics Approaches for Multi-peptide Vaccine Prediction Against Klebsiella oxytoca and Validation Through In Silico Expression.

Authors:  Qudsia Yousafi; Humaira Amin; Shabana Bibi; Rafea Rafi; Muhammad S Khan; Hamza Ali; Ashir Masroor
Journal:  Int J Pept Res Ther       Date:  2021-09-20       Impact factor: 1.931

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.